CD8A and neoplasm: By selectively killing FAP‐α‐expressing CAFs in TME, PIT was not only capable of inducing tumor regression, but simultaneously increasing the levels of IFN‐γ, TNF‐α, and IL‐2 in CD8+ tumor‐infiltrating lymphocytes and synergistically reverting tumor resistance in cells that were previously resistant to 5‐fluorouracil (5‐FU) chemoradiotherapy [303, 304, 305].